Active vs. Passive Surveillance for Identifying Safety Signals
Modified on: Fri, 5 Feb, 2021 at 3:50 PM
Medical product safety is critical for patients’ health and the success of a drug launched after R&D and clinical trials worth billions of dollars. However, the performance of a drug in the post-market scenario is often unpredictable. To identify the unsuspected safety signals, it is now necessary to access and use information from all available real-world data sources such as Claims, EMR, and Genomic (future) data sets. Read More...